{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:28:06Z","timestamp":1794961686632,"version":"4.9.1"},"reference-count":74,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>The aim of this study was to evaluate the relationship between infection with SARS-CoV-2 and autoimmunity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome (SARS) associated coronavirus 2 (SARS-CoV-2). Although most of the infected individuals are asymptomatic, a proportion of patients with COVID-19 develop severe disease with multiple organ injuries. Evidence suggests that some medications used to treat autoimmune rheumatologic diseases might have therapeutic effect in patients with severe COVID-19 infections, drawing attention to the relationship between COVID-19 and autoimmune diseases. COVID-19 shares similarities with autoimmune diseases in clinical manifestations, immune responses and pathogenic mechanisms. Robust immune reactions participate in the pathogenesis of both disease conditions. Autoantibodies as a hallmark of autoimmune diseases can also be detected in COVID-19 patients. Moreover, some patients have been reported to develop autoimmune diseases, such as Guillain--Barr\u00e9 syndrome or systemic lupus erythematosus, after COVID-19 infection. It is speculated that SARS-CoV-2 can disturb self-tolerance and trigger autoimmune responses through cross-reactivity with host cells. The infection risk and prognosis of COVID-19 in patients with autoimmune diseases remains controversial, but patient adherence to medication regimens to prevent autoimmune disease flares is strongly recommended.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>We present a review of the association between COVID-19 and autoimmune diseases, focusing on similarities in immune responses, cross-reactivity of SARS-CoV-2, the development of autoimmune diseases in COVID-19 patients and the risk of COVID-19 infection in patients with preexisting autoimmune conditions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000000776","type":"journal-article","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T00:39:01Z","timestamp":1608165541000},"page":"155-162","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":428,"title":["COVID-19 and autoimmune diseases"],"prefix":"10.1097","volume":"33","author":[{"given":"Yu","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Dermatology, Second Xiangya Hospital, Central South University, Hunan Key Laboratory of Medical Epigenetics, Changsha, Hunan, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr H.","family":"Sawalha","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics, Medicine, and Immunology, and Lupus Center of Excellence, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianjin","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Second Xiangya Hospital, Central South University, Hunan Key Laboratory of Medical Epigenetics, Changsha, Hunan, PR China"},{"name":"Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,12,15]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","DOI":"10.1152\/physiolgenomics.00089.2020","article-title":"The COVID-19 pandemic: a global health crisis","author":"Pollard","year":"2020","journal-title":"Physiol Genomics"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"18778","DOI":"10.18632\/aging.103989","article-title":"SARS-CoV-2, immunosenescence and inflammaging: partners in the COVID-19 crime","volume":"12","author":"Domingues","year":"2020","journal-title":"Aging"},{"key":"R3-20250526","article-title":"Hunting coronavirus by transmission electron microscopy: a guide to SARS-CoV-2-associated ultrastructural pathology in COVID-19 tissues","author":"Hopfer","year":"2020","journal-title":"Histopathology"},{"key":"R4-20250526","first-page":"1","article-title":"In silico modeling for quick prediction of inhibitory activity against 3CL enzyme in SARS CoV diseases","author":"De","year":"2020","journal-title":"J Biomol Struct Dynamics"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41392-020-00318-0","article-title":"Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2","volume":"5","author":"Yu","year":"2020","journal-title":"Signal Transduc Target Ther"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s41423-020-0458-z","article-title":"Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies","volume":"17","author":"Yi","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"R8-20250526","first-page":"9208","article-title":"Advances in SARS-CoV-2: a systematic review","volume":"24","author":"Bai","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"102433","DOI":"10.1016\/j.jaut.2020.102433","article-title":"The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak","volume":"109","author":"Rothan","year":"2020","journal-title":"J Autoimmun"},{"key":"R10-20250526","article-title":"Clinical characteristics of COVID-19 patients with gastrointestinal symptoms in Northern Italy: a single-center cohort study","author":"Schettino","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"552002","DOI":"10.3389\/fmed.2020.552002","article-title":"Clinical characteristics and outcomes of severe and critical patients with 2019 novel coronavirus disease (COVID-19) in Wenzhou: a retrospective study","volume":"7","author":"Qian","year":"2020","journal-title":"Front Med"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.3389\/fimmu.2020.02063","article-title":"Excessive neutrophils and neutrophil extracellular traps in COVID-19","volume":"11","author":"Wang","year":"2020","journal-title":"Front Immunol"},{"key":"R13-20250526","article-title":"Immunobiology and immunotherapy of COVID-19: a clinically updated overview","author":"Esmaeilzadeh","year":"2020","journal-title":"J Cell Physiol"},{"key":"R14-20250526","article-title":"COVID-19 and immunological dysregulation: can autoantibodies be useful?","author":"Pascolini","year":"2020","journal-title":"Clin Transl Sci"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s10787-020-00762-y","article-title":"Innate immune response in systemic autoimmune diseases: a potential target of therapy","volume":"28","author":"Hejrati","year":"2020","journal-title":"Inflammopharmacology"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"16219","DOI":"10.1038\/s41598-020-73371-y","article-title":"Designing a multiepitope peptide based vaccine against SARS-CoV-2","volume":"10","author":"Singh","year":"2020","journal-title":"Sci Rep"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","article-title":"Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity","volume":"183","author":"Rydyznski Moderbacher","year":"2020","journal-title":"Cell"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13045-020-00968-1","article-title":"Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia","volume":"13","author":"Lancman","year":"2020","journal-title":"J Hematol Oncol"},{"key":"R19-20250526","first-page":"227","article-title":"Risk factors and laboratory test results associated with severe illness and mortality in COVID-19 patients: a systematic review","volume":"52","author":"Setiati","year":"2020","journal-title":"Acta Med Indones"},{"key":"R20-20250526","article-title":"Lymphopenia in critically ill COVID-19 patients: a predictor factor of severity and mortality","author":"Ziadi","year":"2020","journal-title":"Int J Lab Hematol"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"108509","DOI":"10.1016\/j.clim.2020.108509","article-title":"Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy","volume":"217","author":"Ciceri","year":"2020","journal-title":"Clin Immunol"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"155302","DOI":"10.1016\/j.cyto.2020.155302","article-title":"Prognostic value of interleukin-18 and its association with other inflammatory markers and disease severity in COVID-19","volume":"137","author":"Sati\u015f","year":"2020","journal-title":"Cytokine"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ijid.2020.09.1438","article-title":"Patients with Covid-19 exhibit different immunological profiles according to their clinical presentation","volume":"101","author":"Vassallo","year":"2020","journal-title":"Int J Infect Dis"},{"key":"R24-20250526","doi-asserted-by":"crossref","DOI":"10.1080\/14737159.2020.1830760","article-title":"Diagnosis of SARS-CoV-2 infection in the setting of cytokine release syndrome","author":"Azar","year":"2020","journal-title":"Expert Rev Mol Diagn"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"102473","DOI":"10.1016\/j.jaut.2020.102473","article-title":"Characteristics and prognostic factors of disease severity in patients with COVID-19: the Beijing experience","volume":"112","author":"Sun","year":"2020","journal-title":"J Autoimmun"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/s41423-020-0492-x","article-title":"Elevated serum levels of S100A8\/A9 and HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19 patients","volume":"17","author":"Chen","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"R27-20250526","doi-asserted-by":"crossref","DOI":"10.23812\/20-1-E","article-title":"Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy","volume":"34","author":"Conti","year":"2020","journal-title":"J Biol Regulat Homeost Agents"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/acr2.11140","article-title":"Intravenous Anakinra for macrophage activation syndrome may hold lessons for treatment of cytokine storm in the setting of coronavirus disease 2019","volume":"2","author":"Wampler Muskardin","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"R29-20250526","first-page":"1629","article-title":"Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19","volume":"34","author":"Conti","year":"2020","journal-title":"J Biol Regul Homeost Agents"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/s41590-020-00814-z","article-title":"Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19","volume":"21","author":"Woodruff","year":"2020","journal-title":"Nat Immunol"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/s41423-020-00542-2","article-title":"Expansion of atypical memory B cells is a prominent feature of COVID-19","volume":"17","author":"Oliviero","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"R32-20250526","article-title":"Unique immunological profile in patients with COVID-19","author":"Varchetta","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"R33-20250526","article-title":"Neutrophil extracellular traps in COVID-19","volume":"5","author":"Zuo","year":"2020","journal-title":"JCI Insight"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/s41467-019-09801-x","article-title":"Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome","volume":"10","author":"Ali","year":"2019","journal-title":"Nat Commun"},{"key":"R35-20250526","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2020.09.1447","article-title":"Tocilizumab therapy of COVID-19: a comparison of subcutaneous and intravenous therapies","author":"Kaminski","year":"2020","journal-title":"Int J Infect Dis"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.5152\/eurjrheum.2020.2056","article-title":"Management strategies for patients with autoimmune diseases during the COVID-19 pandemic: a perspective from China","volume":"7","author":"Liu","year":"2020","journal-title":"Eur J Rheumatol"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"102511","DOI":"10.1016\/j.jaut.2020.102511","article-title":"Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: a retrospective case-control survival analysis of 128 patients","volume":"114","author":"Canziani","year":"2020","journal-title":"J Autoimmunity"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"102537","DOI":"10.1016\/j.jaut.2020.102537","article-title":"High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients","volume":"115","author":"Iglesias-Juli\u00e1n","year":"2020","journal-title":"J Autoimmun"},{"key":"R39-20250526","article-title":"Troublesome friends within us: the role of gut microbiota on rheumatoid arthritis etiopathogenesis and its clinical and therapeutic relevance","author":"Reyes-Castillo","year":"2020","journal-title":"Clin Exp Med"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.27421","article-title":"Everyone comes from somewhere: systemic lupus erythematosus and Epstein-Barr virus induction of host interferon and humoral anti-Epstein-Barr nuclear antigen 1 immunity","volume":"62","author":"Harley","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1136\/annrheumdis-2019-215361","article-title":"Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individuals","volume":"78","author":"Jog","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"102332","DOI":"10.1016\/j.jaut.2019.102332","article-title":"Epstein Barr virus nuclear antigen 1 (EBNA-1) peptides recognized by adult multiple sclerosis patient sera induce neurologic symptoms in a murine model","volume":"106","author":"Jog","year":"2020","journal-title":"J Autoimmun"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.imlet.2019.10.017","article-title":"HLA DR2b-binding peptides from human endogenous retrovirus envelope, Epstein-Barr virus and brain proteins in the context of molecular mimicry in multiple sclerosis","volume":"217","author":"Ramasamy","year":"2020","journal-title":"Immunol Lett"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.molimm.2020.06.017","article-title":"Viral myocarditis involves the generation of autoreactive T cells with multiple antigen specificities that localize in lymphoid and nonlymphoid organs in the mouse model of CVB3 infection","volume":"124","author":"Basavalingappa","year":"2020","journal-title":"Mol Immunol"},{"key":"R45-20250526","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.58603","article-title":"SARS-CoV-2 strategically mimics proteolytic activation of human ENaC","volume":"9","author":"Anand","year":"2020","journal-title":"eLife"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"102556","DOI":"10.1016\/j.autrev.2020.102556","article-title":"Molecular mimicry between SARS-CoV-2 and respiratory pacemaker neurons","volume":"19","author":"Lucchese","year":"2020","journal-title":"Autoimmun Rev"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s12192-020-01148-3","article-title":"Human molecular chaperones share with SARS-CoV-2 antigenic epitopes potentially capable of eliciting autoimmunity against endothelial cells: possible role of molecular mimicry in COVID-19","volume":"25","author":"Marino Gammazza","year":"2020","journal-title":"Cell Stress Chaperones"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s12192-020-01145-6","article-title":"SARS-CoV-2 and Guillain-Barr\u00e9 syndrome: molecular mimicry with human heat shock proteins as potential pathogenic mechanism","volume":"25","author":"Lucchese","year":"2020","journal-title":"Cell Stress Chaperones"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41420-020-00321-y","article-title":"Benchmarking evolutionary tinkering underlying human-viral molecular mimicry shows multiple host pulmonary-arterial peptides mimicked by SARS-CoV-2","volume":"6","author":"Venkatakrishnan","year":"2020","journal-title":"Cell Death Discov"},{"key":"R50-20250526","article-title":"From anti-SARS-CoV-2 immune responses to COVID-19 via molecular mimicry","volume":"9","author":"Kanduc","year":"2020","journal-title":"Antibodies (Basel)"},{"key":"R51-20250526","doi-asserted-by":"crossref","first-page":"e2017539","DOI":"10.1001\/jamanetworkopen.2020.17539","article-title":"Assessment of lupus anticoagulant positivity in patients with coronavirus disease 2019 (COVID-19)","volume":"3","author":"Reyes Gil","year":"2020","journal-title":"JAMA Netw Open"},{"key":"R52-20250526","article-title":"Presence of antiphospholipid antibodies in COVID-19: case series study","author":"Amezcua-Guerra","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R53-20250526","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000813","article-title":"CNS inflammatory vasculopathy with antimyelin oligodendrocyte glycoprotein antibodies in COVID-19","volume":"7","author":"Pinto","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R54-20250526","article-title":"Immune-mediated neurological syndromes in SARS-CoV-2-infected patients","author":"Guilmot","year":"2020","journal-title":"J Neurol"},{"key":"R55-20250526","doi-asserted-by":"crossref","first-page":"100041","DOI":"10.1016\/j.clinpr.2020.100041","article-title":"Cold agglutinin syndrome as a complication of Covid-19 in two cases","volume":"7","author":"Jensen","year":"2020","journal-title":"Clin Infect Pract"},{"key":"R56-20250526","doi-asserted-by":"crossref","DOI":"10.1007\/s10067-020-05359-y","article-title":"High levels of anti-SSA\/Ro antibodies in COVID-19 patients with severe respiratory failure: a case-based review: high levels of anti-SSA\/Ro antibodies in COVID-19","author":"Fujii","year":"2020","journal-title":"Clin Rheumatol"},{"key":"R57-20250526","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/blood.2020006695","article-title":"Red cell-bound antibodies and transfusion requirements in hospitalized patients with COVID-19","volume":"136","author":"Berzuini","year":"2020","journal-title":"Blood"},{"key":"R58-20250526","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1055\/s-0040-1715791","article-title":"COVID-19 and cold agglutinin hemolytic anemia","volume":"4","author":"Maslov","year":"2020","journal-title":"TH Open"},{"key":"R59-20250526","article-title":"Cold agglutinin disease and autoimmune hemolytic anemia with pulmonary embolism as a presentation of COVID-19 infection","author":"Patil","year":"2020","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"R60-20250526","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1007\/s10072-020-04787-7","article-title":"HLA and immunological features of SARS-CoV-2-induced Guillain-Barr\u00e9 syndrome","volume":"41","author":"Gigli","year":"2020","journal-title":"Neurol Sci"},{"key":"R61-20250526","article-title":"SARS-CoV-2 associated Guillain-Barre syndrome in 62 patients","author":"Finsterer","year":"2020","journal-title":"Eur J Neurol"},{"key":"R62-20250526","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1136\/jnnp-2020-324491","article-title":"Guillain-Barr\u00e9 syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic","volume":"91","author":"Uncini","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R63-20250526","first-page":"9695","article-title":"The first case of systemic lupus erythematosus (SLE) triggered by COVID-19 infection","volume":"24","author":"Bonometti","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R64-20250526","article-title":"Adherence to medication in patients with rheumatic diseases during COVID-19 pandemic","author":"Khabbazi","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R65-20250526","article-title":"Impact of COVID-19 pandemic on hospitalisation of patients with systemic lupus erythematosus (SLE): report from a tertiary hospital during the peak of the pandemic","author":"Chuah","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R66-20250526","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/1756-185X.13959","article-title":"Impact of COVID-19 outbreak on rheumatic patients\u2019 perceptions and behaviors: a cross-sectional study","volume":"23","author":"Hassen","year":"2020","journal-title":"Int J Rheum Dis"},{"key":"R67-20250526","doi-asserted-by":"crossref","first-page":"108410","DOI":"10.1016\/j.clim.2020.108410","article-title":"Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients","volume":"215","author":"Sawalha","year":"2020","journal-title":"Clin Immunol"},{"key":"R68-20250526","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.5152\/eurjrheum.2020.20055","article-title":"Coronavirus disease-2019: implication for the care and management of patients with systemic lupus erythematosus","volume":"7","author":"Sawalha","year":"2020","journal-title":"Eur J Rheumatol"},{"key":"R69-20250526","article-title":"Patients with lupus are not protected from COVID-19","author":"Sawalha","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R70-20250526","doi-asserted-by":"crossref","first-page":"102502","DOI":"10.1016\/j.jaut.2020.102502","article-title":"SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: a cross-sectional study on 916 patients","volume":"112","author":"Zen","year":"2020","journal-title":"J Autoimmun"},{"key":"R71-20250526","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13317-020-00141-1","article-title":"Association between autoimmune diseases and COVID-19 as assessed in both a test-negative case-control and population case-control design","volume":"11","author":"Murtas","year":"2020","journal-title":"Auto Immun Highlights"},{"key":"R72-20250526","doi-asserted-by":"crossref","first-page":"e557","DOI":"10.1016\/S2665-9913(20)30227-7","article-title":"COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study","volume":"2","author":"Zhong","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"R73-20250526","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1136\/annrheumdis-2020-218296","article-title":"Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study","volume":"79","author":"Pablos","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R74-20250526","first-page":"9161","article-title":"Imbalance between procoagulant factors and natural coagulation inhibitors contributes to hypercoagulability in the critically ill COVID-19 patient: clinical implications","volume":"24","author":"Voicu","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000776","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T17:22:13Z","timestamp":1748280133000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,15]]},"references-count":74,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000776","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,15]]}}}